Association of Disease Activity with Programmed Cell Death 1 and Its Ligand Programmed Cell Death Ligand 1 Expressions in Lupus Patients
Loading...
Date
2023-01
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
Journal of Rheumatology
Series Info
Journal of Rheumatology;
Scientific Journal Rankings
Abstract
Background: Programmed cell death 1(PD‑1)/programmed cell death ligand 1 (PD‑L1) pathway
is an immune checkpoint implicated in immune tolerance and involved in the pathogenesis of
several autoimmune diseases. Systemic lupus erythematosus (SLE) is an autoimmune disease
with multiple immune dysregulation. This study aimed to determine PD‑1 and PD‑L1 expressed
levels on both CD3 T and CD19 B lymphocytes in SLE patients compared to healthy donors
and their associations with the clinical data and disease activity of those patients.
Patients and Methods: A total of 25 healthy donors and 80 SLE patients were involved in
the study. PD‑1 and PD‑L1 expressed levels on each of CD3 T and CD19 B lymphocytes were
determined in the peripheral blood (PB) using flow cytometry.
Results: The expressed levels of PD‑1 and PD‑L1 on both CD3 T and CD19 B lymphocytes were
significantly higher in PB of SLE group than that of controls (P = 0.01, P = 0.001, P = 0.009, and
P = 0.001). Significant positive associations were found between PD‑1 and PD‑L1 expressions
on both CD3 T and CD19 B lymphocytes with disease activity in SLE group (P < 0.05).
Conclusion: PD‑1 and its ligand PD‑L1 could have a role as regulators for immune activation in
patients with SLE.
Description
Keywords
B lymphocytes,, programmed cell death 1,, programmed cell death ligand 1,, systemic lupus erythematosus, T lymphocytes